Search Result

Results for "

BRCA proteins

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) CDK (1) Deubiquitinase (1) DNA/RNA Synthesis (3) Environmental Pollutants (2) Epigenetic Reader Domain (1) mRNA (1) PARP (5) PROTACs (2) RAD51 (5) Reactive Oxygen Species (ROS) (1) Reference Standards (1)
By Research Areas:	Cancer (15) Endocrinology (1) Inflammation/Immunology (2)
Oligonucleotides:	mRNA (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Oligonucleotides

Targets Recommended: Slit Proteins Synaptic Vesicle Proteins HSP YTHDF

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W327122

BAP1-IN-1 1 Publications Verification	Deubiquitinase	Cancer
BAP1-IN-1 (Compound 8) is a BRCA1 associated protein 1 (BAP1) catalytic activity inhibitor with an IC₅₀ of 0.1-1 μM .

HY-150147

CAM833 1 Publications Verification	RAD51 Apoptosis	Cancer
CAM833 is a potent orthosteric inhibitor of the interaction between *BRCA2* and RAD51 with a K_d of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-100862

BRCA1-IN-2 3 Publications Verification	PARP	Cancer
BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for *BRCA1* with an IC₅₀ of 0.31 μM and a K_d of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)₂/protein interactions .

HY-148183

Homologous recombination-IN-1	RAD51	Cancer
Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC₅₀=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination .

HY-W116007

Octamethylcyclotetrasiloxane	Environmental Pollutants DNA/RNA Synthesis	Endocrinology
Octamethylcyclotetrasiloxane promotes the anchorage-independent growth of MCF-10A and MCF-10F cells. Octamethylcyclotetrasiloxane induces DNA damage, inhibits the expression of DNA-repairing protein BRCA1 under long-term and high-concentration exposure. Octamethylcyclotetrasiloxane exhibits intrinsic estrogenic activity .

HY-W101585

Isoamyl benzoate Isopentyl benzoate	Environmental Pollutants	Inflammation/Immunology
Isoamyl benzoate (Isopentyl benzoate) is a natural aromatic ester compound. Isoamyl benzoate exhibits free radical scavenging capabilities against DPPH and ABTS, with its IC₅₀ values being 9.55 μg/mL and 7455.54 μM TE/g respectively. Isoamyl benzoate can be used in antioxidant research .

HY-168993

BRCA2-IN-2	Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
BRCA2-IN-2 (Compound 3i) has a strong binding affinity to the *BRCA2* protein. BRCA2-IN-2 can inhibit the proliferation of breast cancer cells and scavenge DPPH free radicals. BRCA2-IN-2 has anti-tumor and antioxidant activities .

HY-150958

RAD51-IN-8	RAD51	Cancer
RAD51-IN-8, a new RAD51 binder, is a *RAD51-BRCA2* inhibitor that inhibits the RAD51 BRCA2 protein protein interaction. RAD51-IN-8 also is a protein−protein interaction (PPI) inhibitor. RAD51-IN-8 has inhibitory activity for H4A4 with an EC₅₀ value of 19 μM .

HY-P10516

BRC4 peptide	DNA/RNA Synthesis RAD51	Cancer
BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence .

HY-168722

PROTAC PARP1 degrader-3	PARP PROTACs	Cancer
PROTAC PARP1 degrader-3 (Compound C6) is a PROTAC degrader for PARP1 with a DC₅₀ of 58.14 nM. PROTAC PARP1 degrader-3 exhibits cytotoxicity in cancer cell SW-620 and LOVO with IC₅₀ of 1.63 μM and 2.84 μM. PROTAC PARP1 degrader-3 exhibits a synergistic effect with SN-38 (HY-13704) in BRCA-mutated colon cancer cell with a combination index (CI) of 0.487. (Blue: Ligand for E3 ligase Cereblon (HY-23095); Pink: Ligand for target protein (HY-10619); Black: Linker (HY-16872))

HY-174563

Human OLA1 mRNA	mRNA	Cancer
Human OLA1 mRNA encodes the human Obg like ATPase 1 (OLA1) protein, a member of the GTPase protein family. OLA1 interacts with breast cancer-associated gene 1 (BRCA1) and BRCA1-associated RING domain protein (BARD1), and is involved in centrosome regulation.

HY-168094

PARP1-IN-30	PARP	Cancer
PARP1-IN-30 (Compound 3) is a specific and potent PARP1 inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of PARP1 in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers .

HY-100862R

BRCA1-IN-2 (Standard)	PARP Reference Standards	Cancer
BRCA1-IN-2 (Standard) is the analytical standard of BRCA1-IN-2 (HY-100862). This product is intended for research and analytical applications. BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions .

HY-181561

BRCA2-RAD51-IN-3	RAD51	Cancer
BRCA2-RAD51-IN-3 is a *RAD51-BRCA2* protein-protein interaction inhibitor with an EC₅₀ of 29.35 μM and a K_d of 75.14 μM. BRCA2-RAD51-IN-3 blocks RAD51-BRCA2 binding, impairs homologous recombination in cancer cells, and induces synthetic lethality. BRCA2-RAD51-IN-3 acts in human pancreatic cancer cells and shows no activity in normal pancreatic cells. BRCA2-RAD51-IN-3 can be used for the research of pancreatic cancer .

HY-185459

PCIP-1	PARP Epigenetic Reader Domain	Cancer
PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and *BRCA*-mutant cancers .

HY-171171

NERx 329	DNA/RNA Synthesis	Cancer
NERx 329 is a replication protein A (RPA) inhibitor with an IC₅₀ of 4.9 μM. NERx 329 blocks the interaction between RPA and single-stranded DNA, and induces functional RPA depletion, loss of single-stranded DNA gap protection, chromosome fragmentation and cell death. NERx 329 inhibits the DNA damage response signaling pathway, exhibits broad single-agent anticancer activity, and enhances the activity of DNA-damaging agents. NERx 329 can be used in research related to brca1-deficient breast cancer, non-small cell lung cancer, and brca1-deficient ovarian cancer .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library	4,096 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 4,096 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

4,096 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 4,096 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P10516

BRC4 peptide	DNA/RNA Synthesis RAD51	Cancer
BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence .

Cat. No.	Product Name		Classification

HY-174563

Human OLA1 mRNA		mRNA
Human OLA1 mRNA encodes the human Obg like ATPase 1 (OLA1) protein, a member of the GTPase protein family. OLA1 interacts with breast cancer-associated gene 1 (BRCA1) and BRCA1-associated RING domain protein (BARD1), and is involved in centrosome regulation.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.